SCHEMBL736585

SCHEMBL736585

CC1C(=O)N(CCCN2CCC3(CC3)C(O)C2)CCN1c1ccc(C(F)(F)F)c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.36
ADAMTS5 Q9UNA0 6/20 0.36
GRM2 Q14416 4/20 0.33
HTR1A P08908 3/20 0.32
DRD2 P14416 3/20 0.32
DRD1 P21728 3/20 0.32
DRD4 P21917 3/20 0.32
DRD5 P21918 3/20 0.32
SLC6A2 P23975 3/20 0.32
HRH2 P25021 3/20 0.32
HTR1D P28221 3/20 0.32
HTR2A P28223 3/20 0.32
HTR2C P28335 3/20 0.32
SLC6A4 P31645 3/20 0.32
HTR7 P34969 3/20 0.32
OPRM1 P35372 3/20 0.32
DRD3 P35462 3/20 0.32
OPRD1 P41143 3/20 0.32
OPRK1 P41145 3/20 0.32
HTR2B P41595 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL736584 1.00 NOTUM (0.36) NOTUMADAMTS5GRM2HTR1ADRD2
SCHEMBL734858 0.93 ADAMTS5 (0.41) NOTUMADAMTS5HTR1ADRD2DRD1
SCHEMBL734859 0.93 ADAMTS5 (0.41) NOTUMADAMTS5HTR1ADRD2DRD1
SCHEMBL735228 0.93 ADAMTS5 (0.41) NOTUMADAMTS5HTR1ADRD2DRD1
SCHEMBL736702 0.93 ADAMTS5 (0.41) NOTUMADAMTS5HTR1ADRD2DRD1
SCHEMBL733556 0.91 GRM2 (0.32) ADAMTS5GRM2OPRM1SIGMAR1P2RX7
SCHEMBL734699 0.91 GRM2 (0.32) ADAMTS5GRM2OPRM1SIGMAR1P2RX7
SCHEMBL733555 0.91 GRM2 (0.32) ADAMTS5GRM2OPRM1SIGMAR1P2RX7
SCHEMBL735793 0.91 GRM2 (0.32) ADAMTS5GRM2OPRM1SIGMAR1P2RX7
SCHEMBL733466 0.90 AR (0.37) NOTUMADAMTS5P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US claimed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US claimed
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 NOTUM 4344/4885ADAMTS5 4707/4885GRM2 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.